A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Diabetic Peripheral Neuropathy
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating Painful DPN.
Key Inclusion Criteria:
Diagnosis of diabetes mellitus type 1 or type 2 with
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Boston, Massachusetts 02115, United States